Development and validation of an online predictive model for biochemical recurrence after radical prostatectomy in elderly patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
450 patients (2015-2022), which were randomly divided into a training set (n = 315) and an internal validation set (n = 135) at a 7:3 ratio.
I · Intervention 중재 / 시술
RP at two independent medical centers
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This model demonstrated robust predictive performance across multiple validation sets. The accompanying web-based tool facilitates rapid and individualized risk assessment, aiding in clinical decision-making.
[OBJECTIVE] To develop and validate a novel model for predicting biochemical recurrence (BCR) in elderly prostate cancer (PCa) patients after radical prostatectomy (RP) and to create an accessible onl
- 표본수 (n) 315
APA
Liu J, Tan H, et al. (2026). Development and validation of an online predictive model for biochemical recurrence after radical prostatectomy in elderly patients.. Frontiers in oncology, 16, 1753318. https://doi.org/10.3389/fonc.2026.1753318
MLA
Liu J, et al.. "Development and validation of an online predictive model for biochemical recurrence after radical prostatectomy in elderly patients.." Frontiers in oncology, vol. 16, 2026, pp. 1753318.
PMID
41919261
Abstract
[OBJECTIVE] To develop and validate a novel model for predicting biochemical recurrence (BCR) in elderly prostate cancer (PCa) patients after radical prostatectomy (RP) and to create an accessible online tool for its clinical application.
[METHODS] This retrospective study included patients who underwent RP at two independent medical centers. The initial cohort included 450 patients (2015-2022), which were randomly divided into a training set (n = 315) and an internal validation set (n = 135) at a 7:3 ratio. An independent cohort of 175 patients (2013-2023) was used as the external validation set. Potential predictors were screened via univariable Cox regression. The independent prognostic factors for BCR were subsequently identified via multivariate Cox regression. A predictive nomogram was developed on the basis of these independent factors. The model performance was assessed via time-dependent ROC curves, calibration curves, decision curve analysis (DCA), and Kaplan-Meier (KM) curves.
[RESULTS] Cox multivariate regression analysis revealed that Gleason score (GS), lymph node metastasis (LNM), seminal vesicle invasion (SVI), and free prostate-specific antigen (fPSA) were independent risk factors for BCR after RP in the elderly population (all < 0.05). The nomogram exhibited excellent time-dependent discriminative ability: the AUCs for 2-year, 3-year, and 5-year BCR-free survival were 0.857, 0.915, and 0.916, respectively, in the training set; 0.810, 0.846, and 0.856, respectively, in the internal validation set; and 0.698, 0.679, and 0.715, respectively, in the external validation set. Calibration curves demonstrated good agreement between the predicted BCR risk and actual incidence, and DCA confirmed that the model provides substantial clinical net benefit. We further developed an online tool (https://bcrnomapp.shinyapps.io/bcr-risk/) for personalized BCR-risk prediction.
[CONCLUSION] We developed a validated nomogram based on four independent risk factors-the Gleason score, lymph node metastasis, seminal vesicle invasion, and free PSA-for predicting BCR in elderly prostate cancer patients after radical prostatectomy. This model demonstrated robust predictive performance across multiple validation sets. The accompanying web-based tool facilitates rapid and individualized risk assessment, aiding in clinical decision-making.
[METHODS] This retrospective study included patients who underwent RP at two independent medical centers. The initial cohort included 450 patients (2015-2022), which were randomly divided into a training set (n = 315) and an internal validation set (n = 135) at a 7:3 ratio. An independent cohort of 175 patients (2013-2023) was used as the external validation set. Potential predictors were screened via univariable Cox regression. The independent prognostic factors for BCR were subsequently identified via multivariate Cox regression. A predictive nomogram was developed on the basis of these independent factors. The model performance was assessed via time-dependent ROC curves, calibration curves, decision curve analysis (DCA), and Kaplan-Meier (KM) curves.
[RESULTS] Cox multivariate regression analysis revealed that Gleason score (GS), lymph node metastasis (LNM), seminal vesicle invasion (SVI), and free prostate-specific antigen (fPSA) were independent risk factors for BCR after RP in the elderly population (all < 0.05). The nomogram exhibited excellent time-dependent discriminative ability: the AUCs for 2-year, 3-year, and 5-year BCR-free survival were 0.857, 0.915, and 0.916, respectively, in the training set; 0.810, 0.846, and 0.856, respectively, in the internal validation set; and 0.698, 0.679, and 0.715, respectively, in the external validation set. Calibration curves demonstrated good agreement between the predicted BCR risk and actual incidence, and DCA confirmed that the model provides substantial clinical net benefit. We further developed an online tool (https://bcrnomapp.shinyapps.io/bcr-risk/) for personalized BCR-risk prediction.
[CONCLUSION] We developed a validated nomogram based on four independent risk factors-the Gleason score, lymph node metastasis, seminal vesicle invasion, and free PSA-for predicting BCR in elderly prostate cancer patients after radical prostatectomy. This model demonstrated robust predictive performance across multiple validation sets. The accompanying web-based tool facilitates rapid and individualized risk assessment, aiding in clinical decision-making.
같은 제1저자의 인용 많은 논문 (5)
- A graded approach in East Asian personalized lower blepharoplasty: A retrospective study spanning 12 years.
- Review of complications in double eyelid surgery.
- Spatial transcriptomics and single-cell analyses reveal the role of the cisplatin-resistant gene panel in NSCLC progression and the tumor microenvironment, identifying LOXL2 as a potential therapeutic target.
- Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study.
- CX3CL1/CX3CR1 axis in liver disease: context-dependent roles and balance.